Relay Therapeutics Names Imogen Pryce, Ph.D., Vice President of Strategy and Corporate Affairs

CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#oncologylt;/agt;–Relay
, a new breed of company at the intersection of
computation and biotechnology today announced the appointment of Imogen
Pryce, Ph.D., as vice president of strategy and corporate affairs.

“We are thrilled to welcome Imogen to our executive leadership team,”
said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay
Therapeutics. “She brings a breadth of skills and experience, including
management of strategic and operational challenges across many different
aspects of the biopharma value chain. Imogen’s expertise will be
critical as we enter our next phase of growth and transition into a
development-stage biotechnology company.”

Prior to joining Relay Therapeutics, Dr. Pryce worked in Corporate
Strategy at Shire Pharmaceuticals. There, she managed and contributed to
multiple projects ranging from whole company initiatives to targeted
efforts within specific therapeutic areas and functions. Prior to
joining Shire, she worked at the Boston Consulting Group, where she was
a core member of the health care practice area. She advised senior
client teams on a number of topics, including corporate strategy, M&A
due diligence and R&D portfolio prioritization. She received her Ph.D.
in chemical engineering from the California Institute of Technology and
her Bachelor of Science from the Ohio State University.

About Relay Therapeutics

Relay Therapeutics is committed to creating medicines that will have a
transformative impact on patients by building a unique discovery
platform centered on understanding how the conformation of proteins
relate to function. Whereas prior approaches to imaging proteins have
been limited to static pictures, Relay Therapeutics’ approach overcomes
this challenge by combining unprecedented computational power with
leading edge experimental techniques in structural biology, biophysics,
chemistry and biology. This integration illuminates – for the first time
– the full mobility of a protein and provides key insights into how the
dynamic nature of a protein’s conformation regulates function. By
applying these insights, Relay Therapeutics aims to modulate protein
conformation to develop novel therapies for patients. The company’s
initial programs are focused on developing therapeutics in oncology.
Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a
private company launched in 2016. To date the company has raised $520M
from investors including Third Rock Ventures, SoftBank Vision Fund, GV,
Casdin Capital, BVF Partners, EcoR1 Capital, Foresite Capital,
Perceptive Advisors, Tavistock Group and an affiliate of D.E. Shaw


Dan Budwick
(973) 271-6085

error: Content is protected !!